Medivir’s CEO increases his shareholding in the company

Stockholm, Sweden — Medivir AB (OMX: MVIR) announces that the company’s CEO,
Niklas Prager, has bought 23,600 class B shares in Medivir at an acquisition
price of approximately SEK 2.1 million. The share purchase has occurred within
the framework of an insurance arrangement and will consequently be made public
through this press release and not be reported to the Swedish Financial
Supervisory Authority’s insider register.


For more information please contact:
Niklas Prager, CEO Medivir AB, phone +46 (0)8-407 64 30.

About Medivir
Medivir is an emerging and profitable research‐based pharmaceutical company with
an established marketing and sales organisation in the Nordic region with a
broad portfolio of prescription pharmaceuticals.Medivir receives royalties from
Johnson & Johnson on the global sales of the hepatitis C pharmaceutical,
OLYSIO®. In addition, revenues for sales of OLYSIO in the Nordic region are
generated through the company’s own sales and marketing organisation. Medivir’s
research and development portfolio of pharmaceuticals is based on the company’s
expertise within protease inhibitor design and nucleoside/nucleotide science.
The company’s research and development focus is within infectious diseases and
oncology and the on-going clinical projects in osteoarthritis and neuropathic
pain.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.